logo
logo
OMCL stock ticker logo

Omnicell, Inc.

NASDAQ•OMCL
CEO: Mr. Randall A. Lipps
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Listing Date: 2001-08-09
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Contact Information
4220 North Freeway, Suite 301, Fort Worth, TX, 76137, United States
877-415-9990
www.omnicell.com
Market Cap
$1.56B
P/E (TTM)
751.3
35.4
Dividend Yield
--
52W High
$55.00
52W Low
$22.66
52W Range
36%
Rank31Top 21.6%
5.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$313.98M+0.00%
4-Quarter Trend

EPS

-$0.05+0.00%
4-Quarter Trend

FCF

$20.22M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Total Revenue Growth 7% Total revenues reached $1.185 B USD, marking 7% growth driven by strong service revenue expansion.
Service Revenue Expansion Service revenues increased 8% to $519.1 M USD, reflecting continued demand for technical and SaaS offerings.
Annual Recurring Revenue Growth ARR reached $636 M USD, showing growth from $580 M USD last year, indicating subscription strength.

Risk Factors

Economic Demand Risks Weak economic conditions may reduce demand for capital equipment and impact customer creditworthiness and payment timing.
Net Income Decline Net income fell sharply to $2.1 M USD in 2025 from $12.5 M USD in 2024, signaling margin pressure.
Regulatory Compliance Complexity Evolving laws regarding AI, data security, and DSCSA compliance create significant operational and financial compliance burdens.

Outlook

Autonomous Pharmacy Investment Significant R&D investments continue to advance the Autonomous Pharmacy vision across all care settings via automation.
Flexible Payment Model Shift Expect critical shift in purchasing behavior toward flexible payment models like leasing and subscriptions preserving cash flow.
Artificial Intelligence Integration Substantial investments focus on OmniSphere cloud platform and further development of technology-enabled software and AI services.

Peer Comparison

Revenue (TTM)

ASTH stock ticker logoASTH
$3.18B
+56.4%
TDOC stock ticker logoTDOC
$2.53B
-1.5%
CLOV stock ticker logoCLOV
$1.92B
+40.3%

Gross Margin (Latest Quarter)

TDOC stock ticker logoTDOC
69.3%
-1.8pp
PHR stock ticker logoPHR
68.4%
+0.7pp
TXG stock ticker logoTXG
68.1%
-2.8pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TXG$2.13B-48.7-5.7%15.1%
UFPT$1.57B22.917.4%23.2%
OMCL$1.56B751.30.2%10.3%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
5.2%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow

Deep Research

Next earnings:May 4, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data